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Abstract
Background and objectives: The costs and treatment patterns of attention deficit hyperactivity disorder (ADHD)
are subjects of health services research in Germany and worldwide. Previous publications focused mainly on
prevalent patients and thus research gaps were identified regarding costs and treatment patterns of incident
patients before and after the first diagnosis.
Methods: Analyses were conducted using claims data obtained from a large German sickness fund (Techniker
Krankenkasse). Inclusion criteria consisted of patients with at least two secured outpatient or one inpatient ADHD
diagnosis in 2007. Incidence was ensured by defining a baseline period without ADHD-diagnosis in 2006. In addition to
diseaserelated cost analyses compared to a control group including age group comparisons, comorbidities, the
proportion of multimodal treatment and medication treatment patterns were described.
Results: In total, 9083 newly diagnosed ADHD patients were identified (73 % male; mean age: 12.9 years (SD: 10.3)).
The mean total cost of ADHD patients during the year after the first diagnosis exceeded the mean total cost of the
year before by 976 € (Differencein-Difference-estimator: 1006 €). Our analyses have shown that 10 % of ADHD patients
have been treated with multimodal therapy. In addition, 11 % of the investigated ADHD population have received
methylphenidate or atomoxetine preceeding the date of diagnosis in the relevant observation period.
Discussion: This study provides important insights into the costs as well as the treatment patterns of incident ADHD
patients. ADHD-related costs and medications can be identified prior to the date of the first ADHD diagnosis. Although,
multimodal therapy is presented as an optimal treatment option by many international guidelines and experts, its
proportion for treatment is low (10 %).
Further research is necessary to identify reasons for the low proportion of multimodal therapy and (cost-)effectiveness
has to be evaluated in comparison to other treatment options. In addition, ADHD-related costs could be identified before
the first diagnosis is documented. The reasons for medication prior to diagnosis have to be further investigated.
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Background
Attention deficit hyperactivity disorder (ADHD) is one
of the most common mental disorders among children
and adolescents. The global prevalence has been re-
ported to be between 3 and 5 % [1, 2]. ADHD is defined
as a dysfunctional self-controlling ability. Symptoms of
the disease are characterized by an attention deficit (e.g.
an inability to sustain attention on tasks or activities) ac-
companied with impulsivity and hyperactivity [3, 4].
Symptoms of this heterogeneous behavioral disorder
commonly occur prior to the age of six [5, 6]. Further-
more, direct costs of 341 million € in 2006 demonstrate
the economic burden of ADHD in Germany [7]. For
ADHD treatment, a multimodal therapy consisting of
medication and behavioral treatment is recommended
[6]. Methylphenidate is applied as first-line medication,
while atomoxetine is preferred in cases where existing
comorbidities, like potential drug abuse, are diagnosed.
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Among ADHD patients, approximately 80 % show comor-
bid psychiatric disorders [6]. Therefore, comorbidities
have to be taken into account, because of their impact on
the appropriate choice for treatment. In addition, the cost
structure for patients with comorbidities could differ from
those without comorbidities.
In addition, behavioral treatment is based on occupa-
tional therapy and psychotherapy, as well as interventions
in school. The aim of behavioral treatment is to improve
the coping capabilities of the children. Therefore, patients
need to participate in attention- and self-instruction train-
ing and coaching to sharpen their social skills [2, 8].
Existing studies in Germany focus on prevalent ADHD
patients. This applies to studies focusing on economic
analyses [7, 9–11], as well as publications considering
treatment patterns [12]. Additionally, there is little evi-
dence focusing on incident patients in studies from other
countries. Hodgkins et al. [13] analyzed prescription and
hospitalization data from the PHARMO medical record
linkage database to derive incidence estimates, as well as
persistence and adherence measures for the Netherlands.
Ray et al. [14] analyzed costs for incident ADHD patients
in the US and included the two years before and after pa-
tients’ initial diagnoses within their investigation period.
One German sickness fund (Barmer GEK) conducted ana-
lyses for incident patients. However, that study includes
attention deficit disorder (ADD) patients (i.e. without
hyperactivity), which deviates from the current study [1].
Braun et al. [15] investigated newly diagnosed ADHD
patients as well, but for subgroup analyses of treatment-
persistent patients compared with a drug treatment-
nonpersistent group and nondrug-treated patients. Thus,
the evidence for incident ADHD patients with respect to
costs and therapeutic approaches in early stages of the dis-
ease is low for Germany, and differences between inter-
national health care systems limit the ability to generalize
results from one country to another. Therefore, the aim of
the present study is to close this research gap and calcu-
late the costs of treating newly diagnosed ADHD patients
compared to a control group from the perspective of a
major health insurance fund based on claims data as well
as describing costs by age groups. Comparing costs in the
investigation period before and after the initial diagnosis is
another research focus. The relevance of this research
question arises from the low evidence related to the
amount of costs before the diagnosis compared to after
the diagnosis.
In addition, there is no information whether prescrip-
tions of methylphenidate or atomoxetine are already oc-
curring before diagnosis. Moreover, this study will
analyze whether ergotherapeutic and multimodal treat-
ments were prescribed first, like recommended in the
guidelines, or a single medication strategy was applied
[6]. Furthermore, the comorbidities will be analyzed in
a control group approach as well as in a pre/post
comparison.
Methods
Data and study population
Anonymized claims data from the major German sickness
fund “Techniker Krankenkasse” (TK) were available for
the years 2006 to 2008. This sickness fund covered ap-
proximately 6 million insured people in 2008 who were
available for this study and were studied regarding the in-
clusion criteria [16]. Patient identification was based on
the ICD-10-GM system with ICD codes F90.0, F90.1,
F90.8, and F90.9 defining ADHD. Inclusion criteria re-
quired that at least one secured outpatient diagnosis or
one inpatient principal diagnosis was documented in
2007. For cases identified exclusively by outpatient diag-
nosis, another outpatient diagnosis within the following
three quarters was necessary for inclusion. Therefore, a
second diagnosis could take place in 2008, but the first
diagnosis had to be coded in 2007 and was defined as
index event. In order to identify patients with first-time
ADHD diagnosis and to separate those patients from
prevalent patients during the observation period, patients
with an ADHD diagnosis in 2006 were excluded. Add-
itionally, patients had to be continuously insured from
2006 to 2008 to be included. Since the perspective of a
health insurance fund was used in this analysis, co-
payments are not relevant, as they do not have a budget-
ary impact.
The comparison of costs before and after the first
diagnosis required a follow-up period of 365 days for
each individual. Scientific data validation was conducted.
Besides the basic demographic information (e.g. age and
gender) of the incident ADHD patients, further informa-
tion on outpatient and inpatient care, drug prescriptions,
prescriptions of remedies and aids as well as sick leave
data were available.
Study design
The index event is defined as the date of first diagnosis in
the observation period for each ADHD patient. Since out-
patient diagnoses data is only recorded as a quarter of the
year in German claims data and is the most important
identification source (98.4 %), the beginning of that quarter
was defined as the approximate date of the index event.
For instance, the index date of a patient receiving a first-
time diagnosis in the second quarter of 2007 was set at
2007-04-01. ADHD patients were compared to a 1:3
matched control group adjusted for age and gender. There-
fore, a direct pairwise matching took place with no replace-
ment. The potential control group consists of all TK
insured persons with no ADHD diagnosis in the whole
study period. Furthermore, the index event for the control
group was generated by a random function.
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Costs
Disease- and comorbidity-related costs were identified
using an incremental approach and differences by age were
studied by age stratification (0-5, 6–17 and 18 years and
older). The costs of the index quarter (quarter of diagnosis)
were assigned the year after the index event, because a
large number of ADHD-related treatments were initiated
in that quarter of initial diagnosis. This method has been
applied to avoid overestimation of costs, because the index
diagnosis in the outpatient sector could be only identified
by quarter. To avoid temporal influences and to approxi-
mate disease-related costs when compared with the control
group, the difference-in-difference estimator has also been
calculated. The difference-in-difference estimator com-
pares the pre- and post-cost difference among the ADHD
patients and the control group [17].
Comorbidities
Since the comorbidities related to ADHD could have
an impact on costs, the most important comorbidities
were analyzed. The odds ratio is a proven measure to
verify a higher or lower chance for comorbidities in the
intervention group [18, 19]. Confidence intervals were
calculated using the Newcombe-Wilson method with-
out continuity correction and the methods described by
Armitage and Berry included in an Excel Tool [20–22].
Relevant comorbidities have been derived from the lit-
erature. Studies indicate that major depressive episodes
and recurrent depressive disorders (F32*; F33*); mental
and behavioral disorders due to psychoactive substance
use (F10*-F19*); injuries, poisoning and certain other
consequences from external causes (S00*-T98*); phobic
and other anxiety disorders (F40*; F41*); as well as spe-
cific scholastic skill development disorders of (F81*) are
often related to ADHD [5, 23]. Comorbidities have
been analyzed for each patient in the year after the in-
dividual index event (0 to 364 days). For this purpose,
principal diagnoses of the inpatient sector as well as se-
cured diagnoses of the outpatient sector were included.
Medication and occupational therapy
Atomoxetine (ATC-Code: N06BA09) and methylphenid-
ate (ATC-Code: N06BA04) were identified by their pre-
scription date of service provision and reported as net
values adjusted for co-payments and discounts. Occupa-
tional therapy measures were evaluated using the
national remedy codes 540*, 541* and 542* in conjunc-
tion with the prescription text *Ergo*.
Test statistics
Data management and statistical analyses were performed
with Microsoft Office Excel and Access, as well as with
SPSS by IBM and SAS 9.3. Because there was no normal
distribution for resource utilization and costs identified,
the U-test following Whitney and Mann for two groups as
well as the Kruskal-Wallis test for more than two groups
regarding unpaired samples and the Wilcoxon rank-sum
test for paired samples has been applied. Significance has
been determined at the level of ≤0.05 for all tests.
Results
Patients’ characteristics
In total, 9083 newly diagnosed ADHD patients and 27249
control group members (1:3 matching) were identified ac-
cording to the inclusion criteria. The proportion of male
patients was 73 %. The gender distribution varied signifi-
cantly by age (P = 0.000). Age at the first diagnosis aver-
aged around 12.9 years (SD: 10.3). Male patients were
diagnosed on average at 11.9 years of age, and female pa-
tients at 15.6 years of age. The distribution by age and
gender (Table 1) has shown a decreasing proportion of
male patients with increasing age.
Costs
Costs of the ADHD group in the year after the index event
exceeded the costs before the index event by 976 €. Com-
pared to the control group, incremental costs added up to
720 € before the index event and 1726 € afterward, imply-
ing that the burden of disease is leading to higher costs.
The difference-in-difference (DiD) estimator of the
mean total costs was 1006 €. Furthermore, it can be seen
that 41 % (411€) of costs can be explained by the differ-
ence in costs for ambulatory services (Table 2). In con-
trast, the proportion of pharmaceuticals on total
incremental costs was 13 %. Observing occupational
therapy as part of the costs for remedies and aids in the
ADHD group, occupational therapy was responsible for
51.4 % of costs for remedies and aids before the index
event, increasing to 63.8 % afterwards.
Table 3 consists of the costs regarding the ADHD
group compared to the control group stratified by differ-
ent age groups. Rising total costs can be identified by
Table 1 Patients’ characteristics
Age groups Number of patients (control group) Proportion of the overall amount of ADHD patients Share of male patients in the age group
0–5 619 (1857) 6.8 % 76.9 %
6–17 7226 (21678) 79,6 % 75.4 %
18 and older 1238 (3714) 13.6 % 58.6 %
Total 9083 (27249) 100.0 % 73.3 %
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age (0–5: 1898 €; 6–17: 2160 € and 18 and older: 3239
€). The same trend was identified for the incremental
costs compared to the control group. In contrast to this
trend observed in most service areas, the mean costs of
remedies and medical aids decreased by age.
Comorbidities
The odds ratio for the indication of injury, poisoning, and
certain other consequences of external causes for the
ADHD group compared to the control group after the
index date showed a range of 1.9, increasing to 19.6 for
the indication of specific developmental disorders of scho-
lastic skills. These analyses have shown a remarkable
higher burden of disease for ADHD patients (Table 4).
Treatment
Analyzing medication with methylphenidate, it became ap-
parent that 846 (9.3 %) (atomoxetine: 62 patients; 0.7 %)
patients received this agent in both periods of observation
(before and after the index event). Furthermore, prescrip-
tions of methylphenidate and atomoxetine had already oc-
curred prior to the initial diagnosis. Thus, 3581 ADHD
patients (39.4 %) (atomoxetine: 382; 4.2 %) received treat-
ment with methylphenidate in the year following the index
event, compared to 917 persons (10.1 %) (atomoxetine: 96
patients; 1.1 %) in the year before. The proportion of pa-
tients with prescriptions of both agents increased from
0.34 % before the index date to 2.2 % after the index date.
Occupational therapy is an essential element in ADHD-
treatment. 28.5 % of patients (2590 patients) were treated
with occupational therapy after the index event (before:
18.1 % (1641 patients)). Within the first year following the
index event, 9.6 % % of patients obtained multimodal ther-
apy (Fig. 1). It should be recognized that a rise in the
utilization of multimodal therapy as well as medication
was identified when comparing each treatment before and
after the index event. Furthermore, it has to be noticed
that an increase in the use of multimodal treatment from
the first to the second quarter could be identified, stagnat-
ing afterward.
There is no medication with atomoxetine or methyl-
phenidate as well as multimodal treatment within the con-
trol group in the year before/after the index . Regarding
occupational therapy 754 persons (2.8 %) were treated
with this option after the index date and 902 (3.3 %) be-
fore the index date.
The mean age of those patients receiving occupational
therapy after the index date was 8.3 years (SD: 4.0), which
is 6.4 years lower than the mean of the remaining patients.
This indicates a special application of occupational ther-
apy for younger patients.
Discussion
The objective of this study was to provide real-life informa-
tion on costs and medication treatment patterns before
and after the first diagnosis in the observation period was
coded. Costs of 1006 € were identified in the control group
approach (difference-in-difference). In addition, prescrip-
tion prevalence for methylphenidate were calculated to be
39.4 % respectively, while prescription prevalence was
lower for atomoxetine (4.2 %). This is in accordance with
the German AWMF-guideline, which denotes methylphen-
idate as the first-line medication in ADHD [6]. It has to be
emphasized that some patients were already receiving pre-
scriptions of methylphenidate or atomoxetine in the year
before the initial ADHD diagnosis.
There was a recent published study on prevalent ADHD
patients. Therefore, a comparison of prevalent and incident
patients is possible [24]. If a patient suffers from ADHD
for a longer time, different treatment options could be used
compared to incident patients. This is consistent with the
fact that in the study of the prevalent ADHD patients 59 %
got medication, while in this study 41 % of the incident pa-
tients were treated with medication. Congruently to the
Table 2 Incremental costs of the ADHD group in comparison to the control group before and after the index event (in €)
Type of costs ADHD Group Mean [SD] Control Group Mean [SD] Incremental costs difference-
in-differenceIn the year
before diagnosis
In the year
after diagnosis
In the year
before diagnosis
In the year
after diagnosis
ADHD-group:
After vs.
before diagnosis
ADHD group
to control group
before diagnosis
ADHD group
to control group
after diagnosis
Remedies and aids 251 [507] 367 [603] 106 [475] 104 [578] 116a 145a 263a 118
Outpatient care 430 [485] 801 [674] 189 [266] 149 [299] 371a 241a 652a 411
Outpatient surgery 7 [72] 8 [91] 6 [90] 7 [89] 1 1a 1 0
Inpatient care 395 [2881] 706 [3549] 157 [1734] 147 [1417] 311a 238a 559a 321
Pharmaceuticals 198 [1329] 332 [1245] 128 [3003] 131 [2549] 134a 70a 200a 130
Sick leave
payments
23 [516] 45 [787] 5 [170] 13 [490] 22a 18a 32a 14
Rehabilitation 7 [191] 28 [397] 4 [132] 9 [301] 21a 7a 19a 12
Total 1311 [3502] 2287 [4179] 595 [3622] 560 [3308] 976a 720a 1726a 1006
a:significant difference (at the 0.05-α-level); SD standard deviation
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study of Braun et al. [24] identified rising mean pharma-
ceutical and inpatient costs and decreasing costs of remed-
ies and aids by increasing age like in this study. But while
the mean outpatient costs were decreasing by increasing
age in the study of Braun et al., the outpatient costs in this
paper were rising (age group: 0–5: 661 €, 6–17: 796 €,
18 years and older: 902 €) [24].
These results have also to be discussed in the context
of the international existing literature, even if the com-
parability of country-specific results is limited due to dif-
ferences in the treatment and reimbursement structure
of different health care systems.
Ray at al. [14] reported the costs of ADHD patients in a
control group approach for a period two years before and
after the first diagnosis. The study comprised a data set
from the years 1996 to 2004. The index event was defined
as the first date of an ADHD diagnosis or the prescription
of a relevant ADHD medication. Ray et al. [14] found in-
cremental costs of 986 € one year after the index event
(converted from $ to € with a 2007 exchange rate of
0.74 $/€). In the current study a similar amount of incre-
mental total costs became evident (976 €) [14]. Matza et al.
[25] published a review discussing the direct costs of
ADHD, but did not focus exclusively on incident patients.
A range of 405 € to 1081 € (converted from $ to € with an
average 2004 exchange rate of 0.81 $/€) for the incremental
costs provides a benchmark for the spread of costs among
the matched studies. Comparing the results of Matza et al.
with them of the present study, the costs are within this
spread of Matza et al. [25]. Some caution has to be risen by
Table 3 Costs (€) of the ADHD group in comparison to the control group after the index event by age groups
Type of costs 0–5 years 6–17 years 18 years and older
ADHD Control group ADHD Control Group ADHD Control Group
N = 619 N = 1857 N = 7226 N = 21678 N = 1238 N = 3714
Mean [SD] Mean [SD] Mean [SD] Mean [SD] Mean [SD] Mean [SD]
Median Median Median Median Median Median
Minimum-
Maximum
Minimum-
Maximum
Minimum-
Maximum
Minimum-
Maximum
Minimum-
Maximum
Minimum-
Maximum
Remedies and aidsa 740b [744] 198 [517] 368b [586] 99 [606] 179b [534] 86 [410]
627 0 28 0 0 0
0–3805 0–9056 0–8906 0–48692 0–8229 0–8598
Outpatient care 661b [552] 194 [161] 796b [649] 140 [311] 902b [836] 179 [279]
472 154 619 89 631 94
61–4314 0–1407 0–8709 0–34520 0–7587 0–7451
Outpatient surgerya 24 [170] 16 [137] 7 [83] 6 [77] 8 [81] 13 [120]
0 0 0 0 0 0
0–2912 0–2879 0–2604 0–2873 0–1439 0–3153
Inpatient carea 323b [1259] 146 [752] 641b [3596] 125 [1449] 1280b [3965] 269 [1478]
0 0 0 0 0 0
0–16932 0–20084 0–125854 0–113917 0–42933 0–39432
Pharmaceuticalsa 133b [222] 95 [337] 326b [1246] 110 [1918] 465b [1503] 267 [5112]
67 45 111 21 135 14
0–2417 0–10849 0–33929 0–224394 0–42436 0–304164
Sick leave
paymentsa
- - - - 330b [2110] 98 [1325]
0 0
0–27822 0–40374
Rehabilitationa 17 [222] 13 [232] 22b [337] 7 [247] 74b [683] 24 [532]
0 0 0 0 0 0
0–3814 0–4944 0–12600 0–23733 0–13500 0–28659
Totala 1898b 662 [1182] 2160b [4003] 487 [2834] 3239b [5673] 936 [5703]
1494 291 1355 147 1321 149
61–21540 0–21694 25–125936 0–226983 43–54196 0–304189
asignificant difference between the different ADHS age groups (at the 0.05-α-level); bsignificant difference compared to the control group (at the 0.05-α-level); SD:
standard deviation
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Table 4 Comorbidities by age groups
Comorbidity 0–5 years 6–17 years 18 years and older Sum
ADHD Control
group
Odds Ratio ADHD Control
group
Odds Ratio ADHD Control
group
Odds Ratio ADHD Control
group
Odds Ratio
N = 619 N = 1857 N = 7226 N = 21678 N = 1238 N = 3714 N = 9083 N = 27249
N (%) N (%) (95 % KI) N (%) N (%) (95 % KI) N (%) N (%) (95 % KI) N (%) N (%) (95 % KI)
Depressive episodes/
recurrent depressive
disorders (F32*; F33*)
6 (1.0 %) 0 (0.0 %) - 193 (2.7 %) 63 (0.3 %) 9.4 (7.1–12.5) 552 (44.6 %) 172 (4.6 %) 16.6 (13.7–20.0) 751 (8.3 %) 235 (0.9 %) 10.4 (8.9–12.0)
Mental and behavioral
disorders due to
psychoactive substance
use (F10*-F19*)
0 (0.0 %) 0 (0.0 %) - 40 (0.6 %) 29 (0.1 %) 4.2 (2.6–6.7) 151 (12.2 %) 84 (2.3 %) 6.0 (4.6–7.9) 191 (2.1 %) 109 (0.4 %) 5.3 (4.2–6.8)
Specific scholastic
skill development
disorders (F81*)
8 (1.3 %) 0 (0.0 %) - 1454 (20.1 %) 268 (1.2 %) 20.1 (17.6–23.0) 41 (3.3 %) 5 (0.1 %) 25.4 (10.0–64.4) 1503 (16.5 %) 273 (1.0 %) 19.6 (17.2–22.3)
Phobic and other
anxiety disorders
(F40*; F41*)
11 (1.8 %) 11 (0.6 %) 3.0 (1.3–7.0) 261 (3.6 %) 181 (0.8 %) 4.5 (3.7–5.4) 249 (20.1 %) 76 (2.0 %) 12.1 (9.2–15.7) 521 (5.7 %) 268 (1.0 %) 6.1 (5.3–7.1)
Injuries, poisoning
and certain other
consequences
from external
causes (S00*-T98*)
263 (42.8 %) 512 (27.6 %) 1.9 (1.6–2.3) 2731 (37.8 %) 5481 (25.3 %) 1.8 (1.7–1.9) 422 (34.1 %) 681 (18.3 %) 2.3 (2.0–2.7) 3416 (37.6 %) 6674 (24.5 %) 1.9 (1.8–2.0)
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comparing these studies. The definition of costs and the
study population substantially influences the amount of
total costs. Furthermore, long-term patients might already
receive their optimal medication dose and have better cop-
ing mechanisms [25]. Zeidler et al. [11] examined the ef-
fects of different approaches for cost calculation in claims
data studies (control group approach vs. expert approach).
The authors raised the awareness of methodical transpar-
ence because of the substantial differences in calculated
costs between both approaches.
Age at first diagnosis averaged around 12.9 years and
did not correspond to the ICD-10 criteria, which states
that the disorder should have occurred prior to six years
of age [5]. A reason for the higher mean age at first diag-
nosis in the period of study and the low proportion of pa-
tients diagnosed prior to their sixth year of age (6.8 %)
could be seen in the long period until the final diagnosis.
A study proved a length of 2.6 years for this period [26].
Parr et al. [27] stated a mean age of 8.7 years at first diag-
nosis, while female patients were diagnosed earlier. 56 %
(21 % in our study) of the female patients received their
diagnoses prior to eight years of age and the proportion
was 33 % among the male patients (24 %). A study of the
Barmer GEK dataset analyzed the age at first diagnosis for
AD(H)D patients. The male patients diagnoses were docu-
mented at a mean age of 7.5 and the females diagnoses
were made at an average age of eight. Among the studies
observing incident patients, this analysis is the only one
based on German data. Nevertheless, embedding ADD pa-
tients is a limitation when comparing studies. The study
of Gebhardt et al. [1] included patients without hyper-
activity. A further study of incident patients presented an
average age of 6.7 years at first diagnosis when considering
children between 2 and 10 years of age [14]. The higher
age of female patients at first diagnosis found in the
present study is an indicator that female patients tend to
be classified more often as an inattentive subtype. The
inattention leads to later identification when compared
with the impulsive male patients [28–31].
A large range for comorbidities can be found in the lit-
erature related to ADHD. Kessler et al. [32] computed an
odds ratio for prevalent patients of 2.7 for depressive dis-
eases, an odds ratio of 3.2 for generalized anxiety disor-
ders, and a range of 1.5 to 7.9 for substance abuse. The
current study found an odds ratio of 10.4 for depression
during the follow-up period and thus, this odds ratio is
higher than for the prevalent patients observed by Kessler
et al. [32]. Congruently to the study of Braun et al. [24] it
can be observed that there is a low proportion of patients
with comorbidities in the age group 0 to 5 years except
the comorbidity of injuries, poisoning and certain other
consequences from external causes. The comorbidity of
phobic and other anxiety disorders is increasing by age in
both manuscripts. All available odds ratios by age are
higher than in the study by Braun et al. except specific
scholastic skill development disorders in the age group 18
and older [24]. Therefore, a higher burden of comorbidi-
ties for incident patients can be assumed.
Within the observation period, the age at first diagno-
sis for those who received occupational therapy was
about six years lower than for those patients who did
not get occupational therapy. A methylphenidate pre-
scription for children under six is only granted under ex-
ceptional circumstances. This further strengthens the
importance of behavioral treatments for this age group
[6]. The multimodal therapy is predominantly stated as
central treatment in the literature [33]. A comprehensive
evaluation of behavioral and multimodal treatment for
ADHD is urgently necessary [34].
Limitations
This study provides important insights into the treat-
ment patterns and the costs of incident ADHD patients
in Germany. However, some limitations have to be
917  (10.1%)
96 (1.1 %)
1641 (18.1%)
186 (2.1%)
3581(39.4%)
382 (4.2%)
2590 (28.5%)
955 (9.6%)
Methylphenidate Atomoxetine Occupational
therapy
Multimodal therapy
Forms of treatment pre/post index date (N= 9083)
pre post
Fig. 1 Forms of treatment pre/post index date (N = 9083)
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mentioned in the context of claims data analyses. Al-
though the TK operates nationwide, there could be some
limitations regarding representativeness. As this sickness
fund was established for architects, engineers and techni-
cians and the free choice of the sickness funds is only pos-
sible since 1996, there could be a bias in terms of e.g.
social status [35]. In addition, claims data are primarily
collected for accounting purposes. This results in missing
information for some variables, e.g. the severity of the dis-
ease. Furthermore, it must be mentioned that a one-year
baseline period prior to the defined disease might be short
and incidence could be overestimated. Abbas et al. [36]
have published a methodological review that analyzed the
effect of baseline period length on valid identification of
incident cases. This study verified a 23 to 43 % higher inci-
dence rate depending on the indication of a one-year ad-
justment period compared to an eight-year adjustment
period, which that study defines as the gold standard [36].
Furthermore, there is some evidence supporting the as-
sumption that ADHD was already present prior to the de-
fined index diagnosis. For instance, suspected diagnoses
and prescriptions for methylphenidate and atomoxetine
occurred prior to the index event. However, in this study
the first diagnosis within the investigation period was
explicitly defined as an incidence criterion. Further-
more, ADHD is a chronic disease, which is supposed to
be documented in regular intervals. Therefore, the limi-
tation is solely applicable for individual cases [6].
In addition, the use of methylphenidate is approved for
variant indications. Methylphenidate is licensed for the in-
dication of narcolepsy under the trade name Ritalin [37].
However, there was only one relevant patient with ADHD
and methylphenidate treatment as well as a narcolepsy
diagnosis within the dataset.
Moreover, there are further limitations in the context of
linking occupational therapy with diagnoses. It was barely
possible to identify occupational therapy in association
with psychic or motoric disorders. However, an assign-
ment to ADHD was not feasible because of the lack of as-
sociation with treatment and diagnoses in German claims
data. However, a higher utilization of occupational treat-
ment could be identified due to the control group ap-
proach as a valid measure. A comprehensive demand for
evaluation is postulated in the field of occupational and
multimodal treatments.
Conclusion
In summary, ADHD patients reveal higher resource
utilization compared to a control group, even prior to
the diagnosis. This became recognizable by the higher
costs in the year before diagnosis compared with the
control group as well as by the higher usage of methyl-
phenidate and atomoxetine. Therefore, the reasons for
medication prior to diagnosis have to be further
investigated. Although, multimodal therapy is presented
as an optimal treatment option by many international
guidelines and experts, its proportion for treatment is
low (10 %). Additional research concerning the effect-
iveness of occupational therapy and multimodal treat-
ments in the context of ADHD incidence has to be
performed. Behavioral and multimodal treatments for
ADHD as a whole need a health economic evaluation.
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